When people ask which compounded tirzepatide provider is cheapest, they usually mean one of two very different things — and conflating them is the most common pricing mistake.
Starter price is what you pay at the lowest dose, often just the first month. Full-treatment value is what you pay across the whole course, after you titrate up and stay on for several months. A provider can have the lowest starter price and still be the most expensive over a year if its price climbs at refill or at higher doses.
Why the gap exists
Providers price differently. Some use a low introductory month, then charge more for refills. Some scale price with dose. Some add a separate membership fee. Some advertise a low annual-billing number that does not apply month-to-month. Each structure can make a headline look cheaper than the real cost of treatment.
How to compare honestly
Pick the lens that matches your situation. Trying one month at a low dose? The lowest verified starter price matters most. Expecting to continue 3–12 months and titrate upward? Compare the total over that period, including refills and higher-dose pricing. Always compare the same billing basis: month-to-month against month-to-month, annual against annual. A simple projection — first-month price plus refill price times the months you expect — usually reveals which structure wins for you.
If predictable, dose-independent pricing is what you are after, NexLife publishes a flat rate across the full 2.5–15mg range. It is not always the lowest entry price — a short, low-dose trial may cost less elsewhere.
See NexLife flat-rate plans →Commercial/provider link. Verify current pricing on NexLife's site.